2I9.F KAROLINSKA DEVELOP.AB

Healthcare Biotechnology Frankfurt Exchange
0.0001 EUR
Close of Nov 3, 2026
0.0001 0.0546
Market cap
EUR 75.9K
P/E
-
P/B
0.00x
ROE
-143.5%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 2I9.F undervalued?

Graham number

The Graham number of KAROLINSKA DEVELOP.AB cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

KAROLINSKA DEVELOP.AB fundamental analysis

No fundamental analysis for KAROLINSKA DEVELOP.AB yet.

KAROLINSKA DEVELOP.AB stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About KAROLINSKA DEVELOP.AB

KDventures AB, formerly known as Karolinska Development AB (publ), is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. It seeks to invest in pharmaceutical research and development, medical research, medical innovations, healthcare technology, gene research and development, innovative drug development, drug delivery technologies, biotechnology, and life science tools and service sectors. The firm seeks to invest in …

Full company profile